Mostrando 5 resultados de: 5
Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
ArticleAbstract: Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%–50% of noPalabras claves:covid-19, D614G, point of care testing, rapid diagnoses, SARS-COV-2Autores:Abeseabe R., Allain J.P., Amoroso G., Assennato S.M., Baker S., Barmpounakis P., Bates A., Bergamaschi L., Bermperi A., Blake E., Bousfield R., Boyle A., Bradley J.R., Briggs J.A.G., Brown N., Bucke A., Bundi P., Calder J., Canna L., Chapman D., Chatterjee K., Chiu E., Ciazynska K.A., Clark S., Collier D.A., Crucusio C., Curran M.D., Davidson F., de Jesus R., Demeris N., Domingo J., Dougan G., Elmer A., Emma Jones, Enoch D., Fabiculana M., Foster E., Frost S., Gkrania-Klotsas E., Goel N., Goodfellow I.G., Gupta R.K., Hardwick S., Hardy R., Harris J., Hewitt S., Hosmillo M., James L.C., Jose S., Kennet J., Kiss L., Knock H., Kourampa E., Kourampa J., Lehner P.J., Lyons P.A., Matheson N.J., Meadows A., Mendoza V., Meng B., Mescia F., Mlcochova P., Mynott L., Nathan J.A., O'Brien C., Overhill A., Palmar S., Pasquale C., Perales M., Phillips D., Price J., Ramenatte N., Rastall R., Ribeiro C., Ritchie A., Rowlands J., Rundell V., Saunders C., Shaw A., Sipple J., Skells R., Smith K.G.C., Sparkes D., Temperton N.J., Tordesillas H., Toshner M., Vallier A.L., Vargas P., Vergese B., Vicente I., Watson L., Weekes M.P., Williams A., Wilson M., Worsley J., Xiong X., Zerrudo J.A., Zhang H.Fuentes:scopusSensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
ArticleAbstract: Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in somePalabras claves:Autores:Baker S., Bassi J., Bergamaschi L., Bernardo M. Gutierrez, Betancourt A., Bianchi S., Bowen J., Bower G., Bucke A., Bullman B., Calder J., Cameroni E., Canna L., Collier D.A., Cossetti C., Culap K., Datir R.P., De Marco A., de Sa A., Domingo J., Dougan G., Dunmore B.J., Elmer A., Emma Jones, Epping M., Fawke S., Ferreira I.A.T.M., Fuller S., Garzoni C., Graf S., Grenfell R., Harris J., Hess C., Hewitt S., Hinch A., Hodgson J., Huang C., Huhn O., Hunter K., Jackson S., Jaconi S., Jarvis I., Jose S., Kemp S.A., Kennet J., Kingston N., Kourampa J., Legchenko E., Lehner P.J., Lewis D., Lyons P.A., Marsden J., Martin J., Matara C., Matheson N.J., Meadows A., Meng B., Mescia F., Nice F., Okecha G., Omarjee O., Owehand W.H., O’Brien C., O’Donnell C., Pellanda A.F., Perera M., Pinto D., Pizzuto M.S., Pointon L., Pond N., Price J., Publico C., Rastall R., Ribeiro C., Richoz N., Riva A., Romashova V., Rowlands J., Ruffolo V., Saunders C., Sharma R., Shih J., Silacci-Fregni C., Snell G., Stefanucci L., Stephens J., Strezlecki M., Summers C., Sutcliffe R., Thaventhiran J.E.D., Tilly T., Tong Z., Tordesillas H., Tortorici M.A., Toshner M., Treacy C., Walls A.C., Weekes M.P., Wood J., Wylot M., Yarkoni N.S.Fuentes:scopusRecurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
ArticleAbstract: We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple inPalabras claves:Alpha variant, antibody escape, B.1.1.7, covid-19, deletion, infectivity, neutralizing antibodies, RESISTANCE, SARS-COV-2, spike mutationAutores:Aanensen D.M., Aggarwal D., Alderton A., Amato R., Andersson M.I., Ariani C.V., Awan A.R., Barrett J., Bashton M., Bassett A.R., Bernardo M. Gutierrez, Bonsall D., Bucca G., Bull M., Chand M., Chapman M.H.S., Chauhan A.J., Collier D.A., Connor T.R., Constantinidou C., Corden S., Cottrell S., Curran M.D., Darby A.C., Datir R.P., de Silva T.I., Dewar R., Elliott S., Fairley D.J., Ferreira I.A.T.M., Gallo G., Glaysher S., Golubchik T., Goncalves S., Hamilton W.L., Harrison E.M., Harvey W.T., Hassan-Ibrahim M.O., Hiscox J.A., Holden M.T.G., Jackson D.K., Jahun A.S., Jesudason N.G., Johnston I., Kemp S.A., Kwiatkowski D.P., Langford C.F., Lawniczak M., Li K.K., Livett R., Loman N.J., Loose M.W., Loveson K.F., Lowe H., Ludden C., Lytras S., Marelli S., Martincorena I., Martinez Nunez R.T., McCann C.M., McHugh M.P., McKenna J.P., McMurray C., Meng B., Mlcochova P., Mohamed A., Moore C., Moses S., Nelson A., Nicholls S.M., Osman H., O’Grady J., Pacchiarini N., Page A.J., Pandey S., Papa G., Parker M.D., Parmar S., Paterson S., Prieto J.A., Pybus O.G., Rambaut A., Robson S.C., Saeed K., Shah R.N., Shepherd J.G., Sillitoe J., Smith C.P., Smith D.L., Snell L.B., Taha Y., Templeton K.E., Thakur N., Thomson E.C., Torok M.E., Underwood A.P., Unnikrishnan M., Volz E.M., Wang D., Watkins J., Young G.R.Fuentes:scopusSARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
ArticleAbstract: The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was fiPalabras claves:Autores:Abdullahi A., Abraham P., Agarwal M., Albecka A., Asakura H., Bashyam M.D., Bhat M., Biswas N.K., Brown J., Caputo D., Charles O.J., Chattopadhyay P., Chaudhary U., Chauhan H., Cherian S.S., Chiba M., Chinnaswamy S., Collier D.A., Dalal A., Das S., Datir R.P., Datta M., Datta S., Desai A.S., Devi P., Dhar M.S., Dikid T., Emma Jones, Ferreira I.A.T.M., Goel N., Gogia H., Goonawardane N., Ito J., Kabra S., Kawabata R., Kemp S.A., Kimura I., Kosugi Y., Kumar S., Kumari S., Lall H., Madan P., Maitra A., Mani R.S., Manjunatha M.V., Marwal R., Mayor S., Meena N., Mellan T., Meng B., Mishra S., Mlcochova P., Morizako N., Nagashima M., Nandicoori V., Oberoi J.K., Oide A., Palakodeti D., Pandey R., Papa G., Parida A., Pattabiraman C., Peacock T., Pillai A., Ponnusamy K., Potdar V.A., Prasad P., Radhakrishnan V.S., Raghav S.K., Ramakrishnan U., Raveendran R., Sadamasu K., Saito A., Sarin A., Satwik A., Scaria V., Sengupta S., Seshasayee A.S.N., Sharma R., Sharma U., Shouche Y.S., Singh M.K., Singh P., Singh S., Sivasubbu S., Soni N., Sowpati D.T., Suganami M., Tallapaka K.B., Thangaraj K., Udupi G.A., Uriu K., Vaishya R., Verma K., Wattal C., Whittaker C., Yokoyama M., Yoshimura K., Zhou J.Fuentes:scopusSARS-CoV-2 evolution during treatment of chronic infection
ArticleAbstract: The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for viPalabras claves:Autores:Baker S., Bergamaschi L., Bernardo M. Gutierrez, Betancourt A., Bower G., Bucke A., Bullman B., Bunclark K., Calder J., Canna L., Chandra A., Collier D.A., Cossetti C., Datir R.P., de Bie E.M.D.D., de Sa A., Domingo J., Dougan G., Dunmore B.J., Elmer A., Emma Jones, Epping M., Fawke S., Ferreira I.A.T.M., Fuller S., Gayed S., Gleadall N., Graf S., Grenfell R., Harris J., Hess C., Hewitt S., Hinch A., Hodgson J., Hosmillo M., Huang C., Huhn O., Hunter K., Jackson S., Jahun A.S., Jarvis I., Jose S., Josipovic M., Kemp S.A., Kennet J., Kingston N., Kourampa J., Legchenko E., Lehner P.J., Lewis D., Lumb I.U., Lyons P.A., Mackay M., Marsden J., Martin J., Matara C., Matheson N.J., Meadows A., Mescia F., Mlcochova P., Nice F., Okecha G., Omarjee O., Owehand W.H., O’Brien C., O’Donnell C., Perera M., Pointon L., Pond N., Price J., Publico C., Rastall R., Rees-Spear C., Ribeiro C., Richoz N., Roberts D.J., Romashova V., Rossi S., Rowlands J., Ruffolo V., Saunders C., Sharma R., Shih J., Stefanucci L., Stephens J., Strezlecki M., Summers C., Sutcliffe R., Temperton N.J., Thaventhiran J.E.D., Tilly T., Tong Z., Tordesillas H., Toshner M., Treacy C., Turner L., Weekes M.P., Wood J., Wylot M., Yarkoni N.S.Fuentes:scopus